High performance liquid chromatography determination of doxorubicin and daunorubicin in plasma using UV detection and column switching

Mikan, Antonín; Lanao, José M.; López, Francisco González; Hurlé, Alfonso Domínguez-Gil

doi:10.1002/bmc.1130040408

Cited by 13 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 65:35 (v/v) ratio of water–acetonitrile with a flow rate of 1 mL/min was applied as the mobile phase. The column temperature was maintained at 25 °C, and the wavelength of the UV detector was set to 480 nm . The loading content (LC) and loading efficiency (LE) were calculated based on the following equations DOX releasing profile from the α-La@Fe 3 O 4 -PEI-DOX nanocomposite was assessed by HPLC.…”

Section: Methodsmentioning

confidence: 99%

“…The column temperature was maintained at 25 °C, and the wavelength of the UV detector was set to 480 nm. 31 The loading content (LC) and loading efficiency (LE) were calculated based on the following equations 32 (2) DOX releasing profile from the α-La@Fe 3 O 4 -PEI-DOX nanocomposite was assessed by HPLC. Briefly, 1 mg/mL α-La@Fe 3 O 4 -PEI-DOX dissolved in PBS solutions (100 mM, pH values of 5.5 and 7.4) was incubated at 37 °C while shaking at 200 rpm.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Theranostic α-Lactalbumin-Polymer-Based Nanocomposite as a Drug Delivery Carrier for Cancer Therapy

Delavari

Bigdeli

Mamashli

et al. 2019

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

A nanotheranostic system was developed using α-lactalbumin along with Fe3O4 nanoparticles as an magnetic resonance imaging (MRI) contrast agent for medical imaging and doxorubicin as the therapeutic agent. α-lactalbumin was precipitated and cross-linked using poly(ethylene glycol) and glutaraldehyde. Besides, polyethylenimine was applied to increase the number of amine groups during cross-linking between α-lactalbumin and Fe3O4 nanoparticles. Interestingly, 90% of the initial protein used for the coaggregation process was incorporated in the prepared 130 nm nanocomposites, which facilitated the 85% doxorubicin loading. Formation of pH-sensitive imine bonds between glutaraldehyde and amine groups on α-lactalbumin and polyethylenimine resulted in higher release of doxorubicin at acidic pHs and consequently development of a pH-sensitive nanocarrier. The designed nanocomposite was less immunogenic owing to stimulating the production of less amounts of C3a, C5a, platelet factor 4, glycoprotein IIb/IIIa, platelet-derived β-thromboglobulin, interleukin-6, and interleukin-1β compared to the free doxorubicin. Furthermore, 1000 μg/mL nanocomposite led to 0.2% hemolytic activity, much less than the 5% standard limit. The void nanocarrier induced no significant level of cytotoxicity in breast cancer and normal cells following 96 h incubation. The doxorubicin-loaded nanocomposite presented higher cytotoxicity, apoptosis induction, and doxorubicin uptake in cancer cells than free doxorubicin. Conversely, lower cytotoxicity, apoptosis induction, and doxorubicin uptake were observed in normal cells treated with the doxorubicin-loaded nanocarrier compared to free doxorubicin. In line with the results of in vitro experiments, in vivo studies on tumor-bearing mice showed more suppression of tumor growth by the doxorubicin-loaded nanocomposite compared to the free drug. Moreover, the pharmacokinetic study revealed slow release of doxorubicin from the nanocomposite. Besides, in vitro and in vivo MRI studies presented a higher r 2/r 1 ratio and comparable contrast to the commercially available DOTAREM, respectively. Our findings suggest that this new nanocomposite is a promising nanotheranostic system with promising potential for cancer therapy and diagnosis.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Theranostic α-Lactalbumin-Polymer-Based Nanocomposite as a Drug Delivery Carrier for Cancer Therapy

Delavari

Bigdeli

Mamashli

et al. 2019

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“…Doxorubicin Content Determination Using HPLC. We adapted an HPLC method reported by Mikan et al 14 and Urva et al 15 A stock standard of 65 μg/mL was prepared by placing 0.65 mg of doxorubicin into a 10 mL volumetric flask and diluted in pH 3.0 ddH 2 O to a total volume of 10 mL. A working standard of 20 μg/mL was prepared by transferring appropriate amounts of stock doxorubicin in a 5 mL volumetric flask and diluted in pH 3.0 water to a total volume of 5 mL.…”

Section: Iron Content Determinationmentioning

confidence: 99%

Preparation and Characterization of Novel Magnetic Nano-in-Microparticles for Site-Specific Pulmonary Drug Delivery

McBride¹,

Price²,

Lamoureux³

et al. 2013

Mol. Pharmaceutics

View full text Add to dashboard Cite

We propose the use of novel inhalable nano-in-microparticles (NIMs) for site-specific pulmonary drug delivery. Conventional lung cancer therapy has failed to achieve therapeutic drug concentrations at tumor sites without causing adverse effects in healthy tissue. To increase targeted drug delivery near lung tumors, we have prepared and characterized a magnetically responsive dry powder vehicle containing doxorubicin. A suspension of lactose, doxorubicin and Fe3O4 superparamagnetic iron oxide nanoparticles (SPIONs) were spray dried. NIMs were characterized for their size and morphological properties by various techniques: dynamic light scattering (DLS) and laser diffraction (LS) to determine hydrodynamic size of the SPIONs and the NIMs, respectively; next generation cascade impactor (NGI) to determine the aerodynamic diameter and fine particle fraction (FPF); scanning (SEM) and transmission (TEM) electron microscopy to analyze particle surface morphology; electron dispersive X-ray spectroscopy (EDS) to determine iron loading in NIMs; inductively coupled plasma atomic emission spectroscopy (ICP-AES) and superconducting quantum interference device (SQUID) to determine Fe3O4 content in the microparticles; and high performance liquid chromatography (HPLC) to determine doxorubicin loading in the vehicle. NIMs deposition and retention near a magnetic field was performed using a proof-of-concept cylindrical tube to mimic the conducting airway deposition. The hydrodynamic size and zeta potential of SPIONs were 56 nm and -49 mV, respectively. The hydrodynamic and aerodynamic NIM diameters were 1.6 μm and 3.27±1.69 μm, respectively. SEM micrographs reveal spherical particles with rough surface morphology. TEM and focused ion beam-SEM micrographs corroborate the porous nature of NIMs, and surface localization of SPIONs. An in vitro tracheal mimic study demonstrates more than twice the spatial deposition and retention of NIMs, compared to a liquid suspension, in regions under the influence of a strong magnetic gradient. We report the novel formulation of an inhaled and magnetically responsive NIM drug delivery vehicle. This vehicle is capable of being loaded with one or more chemotherapeutic agents, with future translational ability to be targeted to lung tumors using an external magnetic field.

show abstract

Determination of Doxorubicin and Doxorubicinol in Plasma of Cancer Patients by High-Performance Liquid Chromatography

Bruijn

Verweij

Loos

et al. 1999

Analytical Biochemistry

View full text Add to dashboard Cite

High performance liquid chromatography determination of doxorubicin and daunorubicin in plasma using UV detection and column switching

Cited by 13 publications

References 8 publications

Theranostic α-Lactalbumin-Polymer-Based Nanocomposite as a Drug Delivery Carrier for Cancer Therapy

Theranostic α-Lactalbumin-Polymer-Based Nanocomposite as a Drug Delivery Carrier for Cancer Therapy

Preparation and Characterization of Novel Magnetic Nano-in-Microparticles for Site-Specific Pulmonary Drug Delivery

Determination of Doxorubicin and Doxorubicinol in Plasma of Cancer Patients by High-Performance Liquid Chromatography

Contact Info

Product

Resources

About